ArticleFrontiers in oncology2026
Epidemiological trends and risk factors of early-onset colorectal cancer in the founding BRICS countries, 1990-2023, with projections to 2050.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset colorectal cancer (EOCRC) is increasing globally and represents an emerging public health concern. The BRICS countries (Brazil, Russia, India, China, and South Africa), accounting for ~40% of the global population, lack comprehensive epidemiological characterization. This study evaluates EOCRC burden, risk factors, trends (1990-2023), and projections to 2050. Methods: Using Global Burden of Disease 2023 (GBD 2023) data, we analyzed incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of EOCRC among individuals aged 15-49 years in BRICS countries from 1990-2023, stratified by age, sex, and region. Behavioral, dietary, and metabolic risk factors were assessed for DALY attribution. Decomposition analysis identified drivers of change. SHAP quantified feature importance. A Bayesian Age-Period-Cohort (BAPC) model projected trends to 2050. External corroboration was performed in a retrospective cohort of 236 CRC patients from a tertiary hospital in China using logistic and Cox regression analyses. Results: In 2023, China had the highest age-standardized incidence rate (ASIR) of EOCRC (3.83/100,000), while India had the lowest (1.26/100,000). From 1990-2023, Brazil showed the fastest ASIR increase (EAPC = 1.72), whereas China declined (EAPC =-1.19). Males consistently showed higher burden; in China, incidence in men aged 45-49 was 2.8-fold that of women. Key risk factors included low fiber intake, high red meat consumption, low milk intake, high BMI, and elevated fasting blood glucose, with strong co-occurrence. Decomposition analysis showed population growth and aging as main drivers, while epidemiological change varied, being positive in Brazil and negative for mortality in China. By 2050, India and South Africa are projected to show the largest increases, China will remain high with persistent sex disparities, and Russia will be stable or declining. In clinical corroboration, overweight/obesity was an independent risk factor (aOR = 2.14, 95% CI: 1.09-4.23), and diabetes predicted worse overall survival (HR = 4.35, 95% CI: 1.59-11.93), consistent with GBD-derived metabolic patterns. Conclusions: EOCRC burden varies across BRICS countries and will rise in most regions. Targeted prevention focusing on dietary and metabolic risks, plus early risk-stratified screening, is urgently needed, particularly in high-risk young males. The findings could help inform or guide future prevention and screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.